Objectives Among gynecological tumors, ovarian cancer ranks the first lethallty rate during the last decades. Clinical data had suggested that effective therapy can achieve 90% in ovarian cancer patients when the tumor is still confined to the ovary. However, Almost 75% of patients are diagnosed at advanced stage(III/IV) and exhibit chemotherapy resistance. To find new biomarkers for early diagnosis, therapeutic monitoring and prognostic estimation of ovarian cancer is of great importance. The occurring of liquid biopsy provides a new direction for clinical research of this neoplasm.

Methods Literatures had been searched through datebases using the certain theme of ‘‘‘‘‘ovarian cancer ‘‘‘‘‘ and ‘‘‘‘‘liquid biopsy’’’’’.

Results Liquid biopsy offers a minimally invasive repeatable sample collection of blood. Recent studies attempted to shed light upon their values on early diagnosis, prognosis and prediction of ovarian cancer. Up to now, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and tumor cell-derived exosomes (TEXs) represent the main liquid biopsy approaches.

Conclusions The occurring of liquid biopsy provides a new direction for clinical research of ovarian cancer. Liquid biopsy acts as an effective early detection approach to find new biomarkers for early diagnosis, therapeutic monitoring and prognostic estimation of ovarian cancer.